| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | 35.6% YoY growth this quarter. |
|---|---|
| Margins | Record gross margins of 59.1%; expects 55-56% sustainability. |
| Order book | Order book remains strong across geographies. |
| Demand visibility | Strong order book; softer summer demand in North America noted. |
| Management confidence | High; visibility for doubling revenue within five years. |
Growth
Revenue grew 35.6% YoY to INR841 Cr. PAT surged 173.9% YoY to INR159.4 Cr. EBITDA margin expanded to 25.3%.
Outlook
Guided for FY27 revenue growth of 15-20% and 20-21% EBITDA margin. Target to double revenue in 5 years.
Risks
Geopolitical volatility, shipping hurdles in Middle East, and potential US duty changes are key monitorables.
Last quarter's promises, checked
Delivered
- Guided FY26 Revenue INR 3,000 Cr → delivered INR 2,951 Cr (= BEAT)
- Guided 15-20% Revenue growth → delivered 35.6% (= BEAT)
- Guided 20-21% EBITDA margin → delivered 25.3% (= BEAT)
Partly delivered
- Guided M&A activity in 2027 → delivered QliniQ/ABCnow acquisitions (= PARTIAL)
Investor Presentation filed with BSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹336.95
- Market cap
- ₹15,269 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 29.6×Sector 50.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY
Marksans Pharma Earnings Call Transcript: Key Takeaways
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
- Call
- Guides 20% growth
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma delivered record FY26 performance, crossing ₹3,000cr net income with highest-ever profitability. Strategy focuses on geographic diversification (US, UK, Australia) and transitioning to branded prescription generics.
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on UK/US market expansion and new launches.